Abstract :

Objective: To determine the outcomes of intraplaque verapamil injection for treatment of Peyronie’s disease.

Aim: The purpose of this study is to evaluate the outcomes & efficacy of intraplaque verapamil injection in Peyronie’s disease management.

Methods: The quasi experimental study was conducted from July 2018 to July 2019 on a group of 26 subjects suffering from Peyronie’s disease. After detailed history, complete physical and genital examination, the diagnosis was confirmed. After informed consent, questionnaires regarding pain and sexual satisfaction of patients were filled. All patients received verapamil injections on weekly basis for a period of 10 weeks.  After that, all necessary variables were recorded and data analyzed using SPSS version 16.

Results: Most of the patients in our study were in the age group of 30-65 years. 26.9 % patients were in the range of 51-55 years old. 53.8% patients got no effect of intralesional injection of verapamil on pain while pain relieved in 38.5% of patients  & 7.7% patients experienced an increased in pain intensity after 10 weeks of intralesional injection of verapamil. 61.5%of patients satisfied with their sexual life after 10 week of injections & 30.8% of patients remained unsatisfied with their sexual life while in 7.7%of patients symptoms aggravated. 53.8% of patients experienced no change in size of lesion and curvature of penis, while 30.8% got less than 50% reduction in size of lesion while 15.4% of patients got more than 50% reduction in size after 10 weeks.

Conclusion: This study concluded the efficacy of Verapamil injection for management of Peyronie’s disease.

---

Keywords :

---

References :

1. Campbell MF, Walsh PC, Retik AB. Campbell’s urology. 8th ed. Philadelphia: Saunders, 2002.
2. Peyronie DL. Sur quelques obstacles qui s’opposental’ejaculationnaturelle de la semence.MemAcad R Chir 1743; 1: 425-34.
3. Pryor JP. Peyronie’s disease and impotence.ActaUrolBelg 1988; 56: 317-21.
4. Weidner W, Schroeder-Printzen I, Weiske WH, Vosshenrich R. Sexual dysfunction in Peyronie’s disease: an analysis of 222 patients without previous local plaque therapy. J Urol 1997; 157: 325-8
5. Furey CA. Peyronie’s disease: a treatment by the local injection of meticortelone and hydrocortisone. J Urol 1957; 77: 251-66.
6. Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997; 158: 1388-90.
7. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’sdisease.JUrol 1994; 151: 1522-4.
8. Gomella LG. Impotence — defining the role of minimally invasive therapy. J Urol 1996; 155: 147.
9. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984, J Urol 1991; 146: 1007-9.
10. Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet injection of dexamethasone. J Urol 1975; 114: 898-900.
11. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 1993; 149: 56-8.
12. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts
13. by interferon-alpha, -beta, and -gamma. Scand J UrolNephrol 1991; 25: 89-94.
14. Dang G, Matern R, Bivalacqua TJ, Sikka S, Hellstrom WJ. IntralesionalInterferon-alpha-2B injections for the treatment of Peyronie’s disease. South Med J 2004; 97: 42-6.
15. Wegner HE, Andresen R, Knipsel HH, Miller K. Treatment ofPeyronie’sdisease with local interferon-alpha-2b. EurUrol 1995; 28: 236-40.
16. Wegner HE, Andresen R, Knispel HH, Miller K. Local interferon-alpha-2b is not an effective treatment in early-stage Peyronie’s disease. EurUrol 1997; 32: 190-3.
17. Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection.J Urol. 1997; 158: 1395-9.
18. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaqueinjection of verapamil for Peyronie’s disease. J Urol 2002; 168: 621-5.
19. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urol 1998; 51: 620-6.
20. HellstromWJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon a-2b for minimally invasive treatment for Peyronie’s disease. J Urol 2006; 176: 394-8.